PR Newswire
- Conference Call Scheduled for 8 a.m. EDT Today -
EXTON, Pa., July 24, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the second-quarter 2025 and a fourth-quarter 2025 dividend.
Second-Quarter 2025 Summary (comparisons to prior-year period)
Net sales of $766.5 million increased 9.2%; organic net sales growth was 6.8%.Diluted EPS of $1.82, compared to $1.51 in the same period last year.Adjusted-diluted EPS of $1.84, compared to $1.52 in the same period last year.Updates full-year 2025 net sales guidance range to $3.040 billion to $3.060 billion, up from previous guidance of $2.945 billion to $2.975 billion.Updates full-year 2025 adjusted-diluted EPS guidance range to $6.65 to $6.85, up from the previous range of $6.15 to $6.35.The Company also announces that its Board of Directors has approved a fourth-quarter 2025 dividend of $0.22 per share. The dividend will be paid on November 19, 2025, to shareholders of record as of November 12, 2025.EXTON, Pa., July 21, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced the appointment of Robert McMahon as the company's new Chief Financial Officer (CFO), effective August 4, 2025. Mr. McMahon will succeed Bernard Birkett, CFO, who announced his intention to retire earlier this year. Mr. Birkett will assume the role of Senior Advisor to the CEO through the end of the year to ensure a seamless transition.
EXTON, Pa., July 8, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release second-quarter financial results before the market opens on Thursday, July 24, 2025, and will follow with a conference call to discuss the results and business expectations at 8:00 a.m. Eastern Time.
NEW YORK, July 7, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against West Pharmaceutical Services, Inc. ("West" or the "Company") (NYSE: WST). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
LOS ANGELES, July 7, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against West Pharmaceutical Services, Inc. ("West" or "the Company") (NYSE: WST) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
NEW YORK, July 7, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of West Pharmaceutical Services, Inc. (NYSE: WST).
Shareholders who purchased shares of WST during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
CONTACT US HERE:
LOS ANGELES, July 7, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against West Pharmaceutical Services, Inc. ("West" or "the Company") (NYSE: WST) for violations of the federal securities laws.
Shareholders who purchased the Company's securities between February 16, 2023 and February 12, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before July 7, 2025.
NEW YORK, July 3, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of West Pharmaceutical Services, Inc. (NYSE: WST).
Shareholders who purchased shares of WST during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
CONTACT US HERE:
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In West To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in West between February 16, 2023, and February 12, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
[You may also click here for additional information]
NEW YORK, July 3, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against West Pharmaceutical Services, Inc. ("West" or the "Company") (NYSE: WST) and reminds investors of the July 7, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
NEW YORK, July 2, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against West Pharmaceutical Services, Inc. ("West" or the "Company") (NYSE: WST). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
BENSALEM, Pa., July 1, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against West Pharmaceutical Services, Inc. ("West" or the "Company") (NYSE: WST).
IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN WEST PHARMACEUTICAL SERVICES, INC. (WST), CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE JULY 7, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.
NEW YORK, July 1, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in West Pharmaceutical Services, Inc. ("West Pharmaceutical Services, Inc." or the "Company") (NYSE: WST) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of West Pharmaceutical Services, Inc. investors who were adversely affected by alleged securities fraud between February 16, 2023 and February 12, 2025. Follow the link below to get more information and be contacted by a member of our team:
NEW YORK, June 30, 2025 /PRNewswire/ --
Why: New York, N.Y., June 30, 2025. Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of West Pharmaceutical Services, Inc. (NYSE: WST) between February 16, 2023 and February 12, 2025, both dates inclusive (the "Class Period"), of the important July 7, 2025 lead plaintiff deadline.
So what: If you purchased West Pharmaceutical common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
NEW YORK, June 30, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of West Pharmaceutical Services, Inc. (NYSE: WST).
Shareholders who purchased shares of WST during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
CONTACT US HERE:https://securitiesclasslaw.com/securities/west-pharmaceutical-services-inc-loss-submission-form/?id=154629&from=4
NEW YORK, June 27, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against West Pharmaceutical Services, Inc. ("West" or the "Company") (NYSE: WST). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
NEW YORK, June 27, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in West Pharmaceutical Services, Inc. ("West Pharmaceutical Services, Inc." or the "Company") (NYSE: WST) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of West Pharmaceutical Services, Inc. investors who were adversely affected by alleged securities fraud between February 16, 2023 and February 12, 2025. Follow the link below to get more information and be contacted by a member of our team:
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In West To Contact Him Directly To Discuss Their Options
If you suffered losses exceeding $100,000 in West between February 16, 2023, and February 12, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
[You may also click here for additional information]
NEW YORK, June 26, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against West Pharmaceutical Services, Inc. ("West" or the "Company") (NYSE: WST) and reminds investors of the July 7, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
NEW YORK, June 26, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of West Pharmaceutical Services, Inc. (NYSE: WST).
Shareholders who purchased shares of WST during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
CONTACT US HERE:
NEW YORK, June 25, 2025 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of West Pharmaceutical Services, Inc. (NYSE: WST) between February 16, 2023 and February 12, 2025, both dates inclusive (the "Class Period"), of the important July 7, 2025 lead plaintiff deadline.
So what: If you purchased West Pharmaceutical common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
LOS ANGELES, June 25, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against West Pharmaceutical Services, Inc. ("West" or the "Company") (NYSE: WST).
IF YOU SUFFERED A LOSS ON YOUR WEST INVESTMENTS, CLICK HERE BEFORE JULY 7, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT
The information provided here is not subject to any editorial processing. It is prepared fully automatically and enriched with additional information and further research options. The aim of the content is to provide information seekers with the relevant information quickly and easily. A link back to the information provider and owner ensures that the data prepared here can be compared with the source information if required. The newsboard does not show information in real time. Please contact the exchange operator for this information if required. There is no claim to completeness. High availability cannot be guaranteed. If you notice any errors in the functionality, please let us know using the "Report a Bug" form below.
RAW DATA PROCESSING means that raw data is processed without changing the content. The data is supplemented to improve the interpretation of the information in terms of usability.
Note: The newswire cross-link panel at the top allows you to quickly and easily access additional sources of information. In the terminal view, the news is filtered at company level and enables targeted searches.
On behalf of the trading community, we would like to thank the operators of the trading venues for providing information services.